indications for glp-1 GLP-1s in Oncology: Exploring Risks and Potential Benefits KDIGO 2026: Glucagon-like peptide-1-based therapies

( ), , , , ,

Signal Transduct Target Therapy

The million-dollar question is instead whether semaglutide reduces CV risk independently of its effects on body weight for if so, it would have two powerful implications for clinical practice: (1) relative to other anti-obesity treatments, semaglutide would have an advantage of providing bonus CV protection, making it a preferred option for treating obesity among patients with relatively high risk of CVD

Storing Reconstituted Peptides How a peptide is stored after reconstitution determines whether it stays usable for the full research window or degrades well before its expected shelf life

Until more research is done, most vets advise against using BPC-157 in dogs with known cancer

Body Composition Changes During Weight Reduction With Tirzepatide in the SURMOUNT-1 Study. *Diabetes, Obesity and Metabolism*, 2025